Roche disclosed disappointing Phase 3 data for astegolimab, an anti-ST2 monoclonal antibody targeting chronic obstructive pulmonary disease (COPD). The biologic failed to reduce disease flare-ups, undermining hopes for regulatory approval this year. This follows similar failures by Sanofi and Regeneron’s IL-33 antibody candidates, signaling challenges in this therapeutic class. The string of negative results raises questions about the viability of targeting ST2/IL-33 pathways in COPD and may recalibrate R&D strategies among major pharmaceutical companies focusing on respiratory diseases.